Issues in making a therapeutic choice: recombinant and/or human-derived products.
作者信息
Aledort L M
出版信息
Haemophilia. 2001 Jan;7(1):89-90.
PMID:11136386
Abstract
摘要
相似文献
1
Issues in making a therapeutic choice: recombinant and/or human-derived products.治疗选择中的问题：重组产品和/或人源产品。
Haemophilia. 2001 Jan;7(1):89-90.
2
Recombinant clotting factors in the treatment of hemophilia.重组凝血因子在血友病治疗中的应用
Thromb Haemost. 1999 Aug;82(2):516-24.
3
Switching haemophilia products and inhibitor risk: a United States' perspective.血友病产品转换与抑制物风险：美国视角
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
4
5
The evolution of recombinant factor replacement for hemophilia.血友病重组因子替代疗法的演变
Transfus Apher Sci. 2019 Oct;58(5):596-600. doi: 10.1016/j.transci.2019.08.010. Epub 2019 Aug 9.
6
Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.基于证据的重组FVIIa（诺维乐，尼亚斯塔斯）在儿童和青少年血友病伴抑制剂治疗中的应用。
Transfus Apher Sci. 2008 Feb;38(1):25-32. doi: 10.1016/j.transci.2007.12.002. Epub 2008 Feb 11.
7
Sodium content in products used to treat haemophilia.用于治疗血友病的产品中的钠含量。
Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26.
8
Surgery in haemophilic patients with inhibitors.伴有抑制物的血友病患者的手术治疗
Haemophilia. 2004 Sep;10 Suppl 2:1-2. doi: 10.1111/j.1365-2516.2004.00933.x.
9
The use of facoor VIII and factor IX concentrates during surgery.手术期间使用凝血因子 VIII 和凝血因子 IX 浓缩剂。
JAMA. 1970 Nov 30;214(9):1673-6.
10
Therapeutic properties and safety of recombinant factor VIII and factor IX.重组凝血因子 VIII 和凝血因子 IX 的治疗特性与安全性。
Pol Arch Med Wewn. 2009 Jun;119(6):403-9.
Zotero 插件